PDS Biotechnology Corporation (PDSB) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
PDS Biotech (PDSB) Q1 2026: Versatile 003 Protocol Cut Patient Count by 29%, Accelerating Path to Readout
May 13, 2026
-
PDS Biotech (PDSB) Q4 2025: Phase III Protocol Shift Cuts Trial Duration by 1 Year
March 31, 2026
-
PDS Biotech (PDSB) Q3 2025: Versatile 002 Delivers 39-Month Median OS, Accelerating PFS-Driven Pivot
November 13, 2025
-
PDS Biotech (PDSB) Q2 2025: Net Loss Rises 13% as Phase III HPV16 Trial Advances
August 13, 2025